OKUR

NASDAQ open

OnKure Therapeutics

2.71 USD
▼-0.05-1.81%
盘后 2.51 0.00%
2026-11-20
市值
$109.36M
市盈率
—
EPS
-1.94
股息率
—
52 周区间
2.01 – 5.38
成交量
139.52K
Beta
0.73
目标价
15.25
52W 低 2.0152W 高 5.38
价格走势

公司简介

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.